patient's collecting system, with minimal practice a junior or senior urologist can easily access the collecting system percutaneously using only US imaging. Future clinical trial is needed to test the safety and feasibility of the system.
INTRODUCTION AND OBJECTIVES:
Optical imaging modalities in urological neoplasia possess variable diagnostic accuracy and are unable to provide further characterisation of disease via its stage and grade. There has therefore been a rapid increase in the development of novel imaging methods in urology to address this. We aimed to systematically identify novel optical diagnostic imaging modalities in the detection and staging of urological malignancy, assessing their effectiveness via their utility and accuracy.
METHODS: A systematic literature search utilising MEDLINE, EMBASE and Cochrane Library Database was conducted up to September 2018 by two independent reviewers (OB and QO). Inclusion criteria were studies assessing real-time imaging modalities not already approved in current EAU, AUA and NICE guidelines. Outcome measures extracted were diagnostic accuracy and utility parameters, including feasibility and cost. Risk of bias and quality of evidence was assessed through the QUADAS-2 tool and the GRADE tool respectively. The review was prospectively registered: CRD42018112789.
RESULTS: Of 5475 articles identified, 46 were included. Bladder cancer optical imaging modalities identified included included optical coherence tomography (OCT), confocal laser endomicroscopy, autofluorescence and spectroscopic techniques. OCT remains the most investigated modality with evidence for improving diagnostic accuracy (sensitivity 74.5-100% and specificity 60-98.5%). There is still limited evidence for its use as an intraoperative staging tool. Upper tract malignancies were investigated using photodynamic diagnosis (PDD), narrow band imaging, OCT and confocal laser endomicroscopy. Of these PDD was the only modality to demonstrate consistent improvements in overall diagnostic accuracy through five trials (sensitivity 94-96% and specificity 96.6-100%). There is limited evidence supporting the use of OCT for percutaneous renal biopsy with improvements seen in diagnostic yield only. There is only anecdotal evidence for OCT and PDD use in penile cancer through isolated case series.
CONCLUSIONS: There remains dubious evidence for incorporation into clinical practice for any of the imaging modality identified. However, OCT for bladder cancer and PDD in upper tract malignancy demonstrate the best potential for improvement in overall diagnostic accuracy. Whilst there is an additional potential for use of OCT as an intraoperative staging tool, there is limited evidence for this at present. Further assessment of this modalities is required and on how to best utilise them in clinical practice. intraoperative neuromonitoring using somatosensory evoked potentials (SSEP) is a proven method to detect and prevent brachial plexus injury during neurosurgical procedures. Robotic-assisted laparoscopic prostatectomy (RALP) requires steep Trendelenberg which predisposes patients to the risk of UE neuropraxias. Our study is the first to describe the use of SSEP to decrease risk of UE neuropraxias due to positioning of patients undergoing RALP.
METHODS: SSEP data was collected using a Cadwell Pro. Bilateral ulnar nerves were stimulated with wrist electrodes. Stimulation occurred at a 1.41 Hz rate, 200 usec pulse width and 10-30 mA current throughout the case. Latency and amplitude were prospectively recorded. Established SSEP criteria for intervention (50% loss in amplitude, 10% increase in latency) was used to determine the need for intraoperative repositioning in order to decrease risk of neuropathic damage. Data between April 2016 and July 2018 was retrospectively reviewed to identify patients who satisfied intraoperative intervention criteria and analyzed using SPSS statistical software.
RESULTS: 143 patients received RALP with nerve monitoring. Mean age was 65.2 years (SD 6.7), average weight was 205.6 pounds (SD 33.7) and mean BMI was 30.0 (SD 4.3). Mean operative time was 96.3 minutes (SD 30.2). 14 patients (8.9%) met intervention criteria requiring intraoperative repositioning. Average duration of signal loss meeting interventuon criteria was 22 minutes (SD 5.0). Following repositioning, baseline amplitudes were recovered in 92.9% of patients intraoperatively. One diabetic patient who did not fully recover baseline signals (BMI 42.3, 54 minutes amplitude loss) experienced transient postoperative UE weakness.
CONCLUSIONS: This study is the first to describe the use of SSEP to reduce the risk of UE neuropraxias due to positioning during RALP. Risk of UE nerve injury was identified intraoperatively and prevented in 92.9% of those patients meeting intervention criteria. High risk patients may benefit from pre-surgical selection for nerve monitoring and further analysis to preoperatively stratify patients for SSEP during RALP is currently ongoing. This study also provides proof of concept for the application of nerve monitoring during robotic surgery, which may translate to other urological robotic procedures to prevent UE neuropraxias. 
